Share Name Share Symbol Market Type Share ISIN Share Description
Omega Dia LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.125p -6.12% 17.25p 17.00p 17.50p 18.25p 17.25p 18.25p 58,513 16:19:11
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 12.7 0.7 0.5 34.5 18.76

Omega Diagnostics (ODX) Latest News

More Omega Diagnostics News
Omega Diagnostics Takeover Rumours

Omega Diagnostics (ODX) Share Charts

1 Year Omega Diagnostics Chart

1 Year Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

Intraday Omega Diagnostics Chart

Intraday Omega Diagnostics Chart

Omega Diagnostics (ODX) Discussions and Chat

Omega Diagnostics Forums and Chat

Date Time Title Posts
20/10/201619:17Omega Diagnostics1,345

Add a New Thread

Omega Diagnostics (ODX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Omega Diagnostics trades in real-time

Omega Diagnostics (ODX) Top Chat Posts

Omega Diagnostics Daily Update: Omega Dia is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker ODX. The last closing price for Omega Diagnostics was 18.38p.
Omega Dia has a 4 week average price of 17.10p and a 12 week average price of 17.58p.
The 1 year high share price is 20.75p while the 1 year low share price is currently 13.63p.
There are currently 108,745,669 shares in issue and the average daily traded volume is 121,191 shares. The market capitalisation of Omega Dia is £18,758,627.90.
shanklin: ...Still if the OMX share price went up 5.7% per day every day I could change my mind on this :-)
hyperboreus: Increase in headcount regarding Allersys and growth in Food Intolerance business will inevitably affect profits despite the increase in sales for this year. Any positive news regarding Visitect field trials might give the share price a boost but unless something 'unexpected' occurs, good or bad, I reckon Omega is fairly valued at these levels for the time being as commercial revenues from Visitect are not likely until some time in 2018 assuming all goes well.
barrywhit: Good to see the increase in share price given they are reasonably small trades......
gary38: Omega Diagnostics Group PLC Holding(s) in CompanyIntraday Omega Diagnostics ChartIntraday Omega Diagnostics Chart09/06/2016 8:07amUK Regulatory (RNS & others)TIDMODXRNS Number : 7240AOmega Diagnostics Group PLC09 June 2016TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) --------------------------------------------------------------------------------------------- 1. Identity of the issuer or Omega Diagnostics Group the underlying issuer plc of existing shares to which voting rights are attached: (ii) --------------------------------------------------------------- ---------------------------- 2 Reason for the notification (please tick the appropriate box or boxes): --------------------------------------------------------------------------------------------- An acquisition or disposal of voting rights X ------------------------------------------------------------------- ------------------------ An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached ------------------------------------------------------------------- ------------------------ An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments ------------------------------------------------------------------- ------------------------ An event changing the breakdown of voting rights ------------------------------------------------------------------- ------------------------ Other (please specify): --------------------------------------------------------- -------- ------------------------ 3. Full name of person(s) Richard Edgar Sneller subject to the notification obligation: (iii) ----------------------------------------------------------- -------------------------------- 4. Full name of shareholder(s) (if different from 3.):(iv) ----------------------------------------------------------- -------------------------------- 5. Date of the transaction 8(th) June 2016 and date on which the threshold is crossed or reached: (v) ----------------------------------------------------------- -------------------------------- 6. Date on which issuer 8(th) June 2016 notified: ----------------------------------------------------------- -------------------------------- 7. Threshold(s) that is/are >6% crossed or reached: (vi, vii) ----------------------------------------------------------- -------------------------------- 8. Notified details: ---------------------------------------------------------------------------------------------------------------------- A: Voting rights attached to shares (viii, ix)---------------------------------------------------------------------------------------------------------------------- Class/type Situation previous Resulting situation after the of to the triggering triggering transaction shares transaction if possible using the ISIN CODE ------------- -------------------------------- --------------------------------------------------------------------- Number Number Number Number of % of voting of of of shares voting rights (x) Shares Voting rights Rights ------------- --------------- --------------- -------------- -------------------------- ------------------------- Direct Direct Indirect Direct Indirect (xi) (xii) ------------- ----------- ----------- -------------- ------------ ------------ ------------ ----------- GB00B1VCP282 6,515,000 6,515,000 6,765,000 6,765,000 6.22% ------------- --------------- --------------- -------------- ------------ ------------ ------------ ----------- B: Qualifying Financial Instruments ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Expiration Exercise/ Number of voting % of voting financial date Conversion rights that rights instrument (xiii) Period (xiv) may be acquired if the instrument is exercised/ converted. ----------------- ------------- ------------------------------- ---------------------------- --------------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments (xv, xvi) ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Exercise Expiration Exercise/ Number of voting % of voting financial price date Conversion rights instrument rights (xix, instrument (xvii) period refers to xx) (xviii) --------------- ------------- ------------- ---------------- ---------------------------- ----------------------- Nominal Delta --------------- ------------- ------------- ---------------- ---------------------------- ------------ --------- Total (A+B+C) ---------------------------------------------------------------------------------------------------------------------- Number of voting rights Percentage of voting rights ------------------------------------------------- ------------------------------------------------------------------- 6,765,000 6.22% ------------------------------------------------- ------------------------------------------------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: (xxi) ------------------------------------------------------------------------------- Proxy Voting: ------------------------------------------------------------------------------- 10. Name of the proxy holder: ------------------------------------------------------------- ---------------- 11. Number of voting rights proxy holder will cease to hold: ------------------------------------------------------------- ---------------- 12. Date on which proxy holder will cease to hold voting rights: ------------------------------------------------------------- ---------------- 13. Additional information: ------------------------------------------------------------- ---------------- 14. Contact name: Richard Sneller ------------------------------------------------------------- ---------------- 15. Contact telephone number: 0131 275 2198 ------------------------------------------------------------- ---------------- This information is provided by RNSThe company news service from the London Stock ExchangeENDHOLUKRWRNSANRRR(END) Dow Jones NewswiresJune 09, 2016 04:07 ET (08:07 GMT)Omega Diagnostics Share Price TodayOmega Diagnostics Share Price ChartOmega Diagnostics Share ChatOmega Diagnostics NewsOmega Diagnostics Share Price HistoryOmega Diagnostics DividendOmega Diagnostics TradesOmega Diagnostics Level 2Add Omega Diagnostics to WatchlistAdd Omega Diagnostics to your PortfolioOmega Diagnostics Share Price AlertSwitch to Desktop View By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & ConditionsShare and Investment Glossary Investment Warning Copyright © 1999 - 2016 Cookie and Privacy Policy
arthur_lame_stocks: Maybe the current weakness in the share price is due to a lack of newsflow regarding CD4 development?
hyperboreus: There were two large trades yesterday, the above comment regarding Oryx being just one of them, it will be interesting to see who the other trade relates to. The share price responded positively yesterday and likewise today but interesting to note that is still below the 17p placing in May 2013 that raised £4 million. I think that Oryx have timed their purchase perfectly, for what it is worth I have recently tripled my original holding that I have held since 2012 taking full advantage of a share price around 14p
rivaldo: The current share price is easily justified on the core business alone, which: - is producing around 1.3p EPS - is backed up with a nice cash pile - should continue to grow nicely given the specialisms in growth areas like food intolerance and infectious disease - and the Indian facility is being completed and should provide lower cost production Meanwhile CD4 and Automated Allergy are in the price for free. Happy to hold.
rivaldo: Nice buying this morning, the latest at 16.8p - having a good effect too. Given the forecast 1.3p EPS this year - and the cash pile - the blue sky projects for CD4 and allergens are in the share price for nothing, so with the positive signs in this week's trading update ODX looks pretty cheap to me at these prices. OT : agreed re SCE having multibagger potential, but of course it's dependent on that "gamechanger" news coming through.
rivaldo: Shares Mag today believes ODX is a Buy at these prices: "Omega to bounce back Sell-off due to CD4 set-back looks overdone A sell-off due to delays to a mobile HIV diagnostic’s trials is a buying opportunity at Omega Diagnostics’ (ODX:AIM). Shares in Omega, which specialises in making food intolerance, allergy and infectious disease diagnostics, collapsed 22.8% on news that Visitect Cd4 will have to undergo further development due to stability issues. Data collected by the device during initial tests deteriorates if left at room temperature for five weeks. The company is working on improving the device, which means further delays to the start of field evaluations. Omega’s products generated £12 million in sales last year and the recent share price fall means that investors can buy at 13.5 times finnCap’s 1.3p March 2016 earnings per share forecast. Cd4 is expected to be the first disposable mobile HIV monitoring device to hit the market. The appeal of the device is that it can generate results on the spot, therefore removing the need for the results to be sent to a lab. This is not the first time that Cd4 has been delayed. Tests have to be repeated in Kenya following inconclusive results, despite positive data generated during trials in India. We remain fans for now but will keep a close eye on future operational developments. Shares says:   CD4 bumpy ride to market continues, but has helped cheapen access to Omega’s existing portfolio at 17.6p."
rivaldo: The core business, with 1.3p historic EPS and £2m cash, justifies the current share price on its own, with nothing in it at all for CD4 or for the panel of 40 allergens. The results actually came in slightly ahead of Finncap's expectations, with 1.3p EPS (1.2p forecast), £1.8m EBITDA (£1.5m forecast) and £2m cash (£1.9m forecast). Finncap retain their 28p target price and leave their 2016 forecasts unchanged at 1.4p EPS. Once the CD4 storage issue is sorted out then you can be sure that ODX will RNS it and the share price will be well up from here.
Omega Diagnostics share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20161020 19:37:49